ADORA3 and inflammatory bowel disease: Notably, previous evidence [15] demonstrating the modulatory role of adenosine A3 receptors in the regulation of colonic neuromuscular functions in the presence of bowel inflammation led researchers to hypothesize the potential application of the A3AR agonist as a suitable tool for the management of IBD patients characterized by enhanced bowel motor activity and diarrhea.